Abstract
Objective To estimate coronavirus disease 2019 (COVID-19) mortality rates among individuals incarcerated in U.S. state prisons by race and ethnicity (RE).
Design Retrospective population-based analysis
Setting Data from state-level Departments of Corrections (DOCs) from March 1 through October 1, 2020.
Participants Publicly available data collected by Freedom of Information Act requests representing adults in the custody of US state DOCs.
Main Outcomes Cumulative COVID-19 death and custody population data. Crude RE-specific cumulative death rates per 1,000 persons, by state and in aggregate, using RE-specific custody population on March 1, 2020, as the denominator. Rate ratios (RR) and 95% confidence intervals (95%CI) compared state-level and aggregate cumulative age-adjusted mortality rates as of 10/01/2020 by RE, with White individuals as reference group.
Results Of all COVID-related deaths in U.S. prisons through October 2020, 23.35% (272 of 1165) were captured in our analyses. The average age at COVID-19 mortality was 63 years (SD=10 years) and was significantly lower among Black (60 years, SD=11 years) compared to White adults (66 years, SD=10 years; p<0.001). In age-standardized analysis, COVID-19 mortality rates were significantly higher among Black (RR=1.93, 95% CI: 1.25-2.99), Hispanic (RR=1.81, 95% CI: 1.10-2.96) and those of Other racial and ethnic groups (RR=2.60, 95% CI: 1.01-6.67) when compared to White individuals.
Conclusions Age-standardized mortality rates were higher among incarcerated Black, Hispanic and those of Other RE groups compared to their White counterparts. Greater data transparency from all carceral systems is needed to better understand populations at disproportionate risk of COVID-19 morbidity and mortality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MCJ is supported by the Brigham and Women's Hospital Richard Nesson Fellowship. MCJ, JF, DK were supported by The JPB Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Partners Massachusetts General Brigham IRB Committee gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
